Efficacy of L-Asparaginase Combination Therapy in Localized Extra
Journal of Hematology & Thromboembolic Diseases

Journal of Hematology & Thromboembolic Diseases
Open Access

ISSN: 2329-8790

+44 7868 792050

Research Article - (2013) Volume 1, Issue 2

Efficacy of L-Asparaginase Combination Therapy in Localized Extranodal NK/T-Cell Lymphoma: A Single Institution Experience

Mohamed Amine Bekadja1, Samira Bouchama1, Leila Charef1, Nabil Yafour1, Badra Entasoltan1, Abdessamed Arabi1, Rachid Bouhass1 and Mohamed Brahimi1,2*
1Department of Hematology and Cell Therapy, Institution University Hospital, Algeria
2Department of Hemobiology, Institution University Hospital, Algeria
*Corresponding Author: Mohamed Brahimi, Department of Hemobiology, Institution University Hospital, 269 Hai, Ennakhla Canastel 31132 Oran, Algeria, Tel: 00213 771 485739, Fax: 00213 41 42 16 36 Email:


Background: Nasal extranodal natural killer (NK)/T-cell lymphoma are highly aggressive diseases with a poor outcome. Several studies have shown the interest of L-asparaginase in salvage therapy and first-line L-asparaginase combination therapy for advanced stage extranodal NK/T-cell lymphoma should be tested in prospective trials. We report the first experience of treatment with L-asparaginase in salvage therapy and front-line based- regimen in localized nasal NK/T-cell lymphoma.

Patients and methods: We reviewed 13 consecutive localized stages I/II nasal NK/T cell lymphomas, treated in our institution over a 6 years period. 8 patients were treated with CHOP (cyclophosphamide, doxorubicin, oncovin and prednisone) regimen in first-line chemotherapy and with L-asparaginase-based regimen in salvage therapy. Five patients were treated with first-line chemotherapy, including L-asparaginase-based treatment. We report our results in a single retrospective study of these patients with localized stage NK/T-cell lymphoma.

Results: The overall response was 70% and the OS was 54% at 52 months. Conclusion: These data confirm the efficacy of L-asparaginase-containing regimens in extranodal nasal NK/Tcell lymphoma.

Keywords: L-asparaginase; NK/T-cell lymphoma; Nasal type; Localized stage


Extranodal NK/T cell lymphoma, a nasal type lymphoma, is a distinct entity by the WHO classification of lymphomas [1], with a frequency of less than 1% of all non Hodgkin lymphoma (NHL) in the West [2] and in the North of Africa [3] and an increased incidence in Asia [4]. NK/T-cell lymphoma characterized by a CD3e phenotype, with no surface CD3 or T-cell receptor expression, an activated cytotoxic profile with perforin, granzyme B expression, and common expression of CD56 [5-7]. There is no consensual treatment. In stage I/II nasal extranodal NK/T-cell lymphoma, radiotherapy alone is initially effective but final outcome is unsatisfactory because of frequent systemic progression or relapse [8-13].

In contrast, patients who have extensive disease or who relapse after radiotherapy have a very poor outcome [14].

Patients and Methods

From January 2006 to December 2012, 13 patients with localized stage primary extranodal NK/T-cell lymphoma nasal type, were diagnosed at the Institution University Hospital, 1st November 1954, Oran, Algeria. Eight patients were treated with anthracycline-based regimens (CHOP) in first-line and 6 of them were treated with L-asparaginase-based chemotherapy salvage therapy. Five patients were treated with L-asparaginase front-line therapy and were analyzed in this study.

All patients were informed of the nature and possible adverse reactions of these protocols.

The patients would be included, if they met the following criteria: diagnosis of NK/T-cell lymphoma on primary biopsy of the nasopharyngeal region with a panel of monoclonal antibodies (CD3c, CD20, CD4, CD8, CD56, TIA-1, CD30, LMP-1) CD3e+, CD202 phenotype and markers of EBV (Epstein Bar Virus). Staging consisted of a complete history taking and physical examination, routine blood tests and serum chemistry before treatment. Computed tomography (CT) of the head, neck, thorax, and abdomen was always used to determine the extent of the primary lesion. All patients received protocols with L-asparaginase 6000 U/m2 (Kidrolase-, OPI,Lyon, France) either i.v. on days 2, 4, 6, and 8 combined with methotrexate 3 g/m2 on day 1 before the first asparaginase infusion at each cycle, with folinic acid rescue and dexamethasone 40 mg for 4 days, at the beginning of each cycle. All patients received consolidation radiotherapy (30 Gy) after completion with asparaginase therapy.

Asparaginase toxicity was monitored by complete blood cell count, coagulation tests, antithrombine, amylase, glycemia, bilirubin, aspartate aminotransferase, and alanine aminotransferase measurements.

Response criteri

The treatment responses were assessed using adapted Cheson’s standard criteria [15].

Complete response (CR) was defined as no evidence of residual disease; a partial response as at least a 50% reduction in tumor burden compared with the beginning of treatment; and no response as less than a 50% reduction in tumor burden or disease progression. Responses were assessed from clinical, radiological and laboratory studies prescribed by the individual clinicians.


Baseline characteristics

The characteristics of the patients are shown in table 1. Median age was 42 years (range 21-63 years). 7 patients were female and 6 were males. At diagnosis, the nasal cavity was involved in all patients and systemic B symptoms were present in nine patients. Patients were staged according to the Ann Arbor classification and all were in stage I-II. The median of follow-up was 14 months (5-52 months). According to the IPI classification, 4 patients were IPI=0, 3 patients with IPI=1 and 6 patients with IPI=2.

  Number of Patients (n)
Total 13
International Pronostic Index (IPI):

Stage I and II
Stage A
Stage B


Table 1: Patients’ characteristics.

Patient outcomes

Among the 8 patients who treated with CHOP regimen, two of them achieved complete remission (CR) and six patients were refractory to their first treatment (CHOP) (Table 2). 2 (25%) of them had CR after the asparaginase-based regimen. In this group, the overall survival (OS) was 37.5% at 52 months and the median of OS was 10 months (4.5-15.5 months. Five patients received the Asparaginase-containing regimen as first-line treatment and 4 of them (80%) achieved CR (Table 2). The OS was 80% at 30 months and the median of OS was not reached (Figure 1). In all patients, the overall response (CR+PR) was 70% and the OS was 54% at 52 months.

Protocole CR PR Progression Alive/died OS
CHOP (n=8) 2 0 6 8/0 -
CH CHOP/Aspa(n=6) 2 1 3 3/3 38% at 52 months
Aspa (n=5) 4 0 1 5/0 80% at 30 months
Total (n=13) 8 1 4 10/3 54% at 52 months
Aspa=L-asparaginase; CHOP=cyclophosphamide, doxorubicin, oncovin, prednisone.

Table 2: Outcomes according the treatment with CHOP, CHOP/Aspa and Aspa.

The responses were usually very rapid and rapid responses were also seen after only one course of asparaginase-containing regimen.


Figure 1: Overall survival of all patients.


No documented thromboembolic event was reported. Hematopoietic toxicity was mild, neutropenia of grades 3 and 4 occurred in two patients. No diabetes or pancreatitis was observed. Three patients died and two of them (refractory to their first treatment) died from sepsis one month after the last course of asparaginase, without detectable disease.


In stage I/II nasal NK/T-cell lymphoma, radiotherapy alone is initially effective but final outcome is unsatisfactory because of frequent systemic progression or relapse (CR rate: 60-70%, 5-year OS: 40-60%) [16-18]. It has therefore been suggested that systemic treatment should be combined with radiation in localized nasal NK/T-cell lymphoma and some researchers have reported promising results with radiotherapy followed by combination chemotherapy (5-year OS: 75-87%) [18,19].

Six patients were refractory to their first treatment with anthracycline-based regimens (CHOP). After the salvage therapy with L-asparaginase-based chemotherapy, three patients achieved CR.

The anthracycline-based chemotherapy produced a CR rate of 36%, a median DFS of 10 months and a median OS of 19 months [20]. These results were still inferior to the results of the L-Asparaginase-based regimen in nasal NK/T cell lymphoma salvage therapy [21-26].

Our study also showed a better CR rate (33%) after salvage therapy with asparaginase than those containing anthracycline-based (Table 2). The overall response with asparaginase-based chemotherapy was (CR+PR) 80%.

After the results obtained with L-Asparaginase salvage therapy in patients with refractory NK/T-cell lymphoma in our institution, we started in March 2010, the study in localized stage nasal NK/Tcell lymphoma with the patients who received the Asparaginasecontaining regimen in first-line therapy. At the time to 31 December, five patients were included and the overall results obtained, showed that L-asparaginase-based chemotherapy as first-line treatment produced a CR rate of 80% in all patients in stage I/II nasal NK/T-cell lymphoma and all of them remained in complete remission with an OS=80% at 30 months. All of the five patients responded nicely and the tumor regressed after the first cycle.

In our study, the L-asparaginase-based chemotherapy produced a CR rate of 80 % in first-line therapy and 33% in the salvage therapy, a median OS in all 13 patients was not reached with 54% of survival in 52 months. In conclusion, our study showed that asparaginase administered in patients with stage I/II nasal NK/T-cell lymphoma is effective and should be explored further.


The authors of this manuscript are grateful to all the participants: Miss Mehalli Samira, and Miss Benmir Imene.

We are indebted to the following pathologists for sending cases: J. Audouin (Hôpital Hôtel Dieu, Paris), F. Benali (EHU 1st November, Oran), F. Hacene (EHU 1st November, Oran). All authors participated in the study conception and/or acquisition of data. The manuscript was approved by all authors.


  1. Jaffe ES, Lee Harris N, Stein H, Vardiman JW (2001) Tumors of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumors. IARC Press.
  2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17: 3835-3849.
  3. Kluin PM, Feller A, Gaulard P, Jaffe ES, Meijer CJ, et al. (2001) Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology. Histopathology 38: 250-270.
  4. Ryder J, Wang X, Bao L, Gross SA, Hua F, et al. (2007) Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature. Int J Hematol 85: 18-25.
  5. Emile JF, Boulland ML, Haioun C, Kanavaros P, Petrella T, et al. (1996) CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 87: 1466-1473.
  6. Oshimi K (2007) Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139: 532-544.
  7. Jaffe ES (1995) Nasal and nasal-type T/NK cell lymphoma: a unique form of lymphoma associated with the Epstein-Barr virus. Histopathology 27: 581-583.
  8. Ribrag V, Ell Hajj M, Janot F, Girinsky T, Domenge C, et al. (2001) Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 15: 1123-1126.
  9. Chen HH, Fong L, Su IJ, Ting LL, Hong RL, et al. (1996) Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma: a retrospective analysis covering a 34-year period. Radiother Oncol 38: 1-6.
  10. Sobrevilla-Calvo P, Meneses A, Alfaro P, Bares JP, Amador J, et al. (1993) Radiotherapy compared to chemotherapy as initial treatment of angiocentric centrofacial lymphoma (polymorphic reticulosis). Acta Oncol 32: 69-72.
  11. Aviles A, Rodriguez L, Guzman R, Talavera A, Garcia EL, et al. (1992) Angiocentric T-cell lymphoma of the nose, paranasal sinuses and hard palate. Hematol Oncol 10: 141-147.
  12. Logsdon MD, Ha CS, Kavadi VS, Cabanillas F, Hess MA, et al. (1997) Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 80: 477-488.
  13. Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, et al. (1997) CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 97: 821-829.
  14. Berk V, Yildiz R, Akdemir UO, Akyurek N, Karabacak NI, et al. (2008) Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules: utility of 18F-FDG PET in staging. Clin Nucl Med 33: 365-366.
  15. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586.
  16. Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, et al. (2006) Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 106: 609-615.
  17. Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, et al. (2000) Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 18: 54-63.
  18. Li YX, Coucke PA, Li JY, Gu DZ, Liu XF, et al. (1998) Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 83: 449-456.
  19. Avilés A, Díaz NR, Neri N, Cleto S, Talavera A (2000) Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 22: 215-220.
  20. Reyes F, Lepage E, Munck JN, et al. Superiority of chemotherapy alone with the ACVBP regimen over treatment with three cycles of CHOP plus radiotherapy in low risk localized aggressive lymphoma: The LNH93-1 GELA Study. Proc Am Soc Hematol.
  21. Matsumoto Y, Nomura K, Kanda-Akano Y, Fujita Y, Nakao M, et al. (2003) Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 44: 879-882.
  22. Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, et al. (2003) L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78: 163-167.
  23. Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, et al. (2006) Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol 24: 28-32.
  24. Nagafuji K, Fujisaki T, Arima F, Ohshima K (2001) L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 74: 447-450.
  25. Obama K, Tara M, Niina K (2003) L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 78: 248-250.
  26. Jaccard A, Petit B, Girault S, Suarez F, Gressin R, et al. (2009) L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 20: 110-116.
Citation: Bekadja MA, Bouchama S, Charef L, Yafour N, Entasoltan B,et al. (2013) Efficacy of L-Asparaginase Combination Therapy in Localized Extranodal NK/TCell Lymphoma: A Single Institution Experience. J Hematol Thromb Dis 1:109.

Copyright: © 2013 Bekadja MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.